

Keytruda® (pembrolizumab), Lenvima® (lenvatinib) – Expanded indication

- On August 10, 2021, the <u>FDA approved</u> Merck's <u>Keytruda (pembrolizumab)</u>, in combination with Eisai's <u>Lenvima (lenvatinib)</u>, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
 - Keytruda was previously approved in combination with <u>Inlyta[®] (axitinib)</u>, for the first-line treatment of adult patients with advanced RCC.
 - Lenvima was previously approved in combination with everolimus, for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy.
- In addition to RCC, Keytruda is also approved for melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer, MSI-H or dMMR colorectal cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, endometrial carcinoma, tumor mutational burden-high cancer, cutaneous squamous cell carcinoma, and triple-negative breast cancer.
- In addition to RCC, Lenvima is approved for differentiated thyroid cancer, hepatocellular carcinoma, and endometrial carcinoma.
- The approval of the expanded indication was based on KEYNOTE-581, an open-label, randomized study in 1,069 patients with advanced RCC. Patients were randomized to one of the following treatment arms: Keytruda in combination with Lenvima; Lenvima in combination with everolimus; or Sutent® (sunitinib). The major efficacy outcome measures were progression free survival (PFS) and overall survival (OS). An additional efficacy outcome measure was confirmed objective response rate (ORR).
 - Median PFS was 23.9 months with Keytruda plus Lenvima vs. 9.2 months with Sutent (hazard ratio [HR] 0.39, 95% CI: 0.32, 0.49; p < 0.0001).
 - Median OS was not reached with Keytruda plus Lenvima or Sutent (HR 0.66, 95% CI: 0.49, 0.88; p = 0.0049).
 - The confirmed ORR was 71% and 36% with Keytruda plus Lenvima vs. Sutent, respectively (p < 0.0001).
- The recommended dose of Keytruda for use in RCC with Lenvima is 200 mg intravenously every 3 weeks or 400 mg every 6 weeks. The recommended dose for Lenvima is 20 mg orally once daily. Keytruda plus Lenvima is administered until disease progression, unacceptable toxicity, or for up to 24 months. After completing 2 years of combination therapy, Lenvima may be administered as a single agent until disease progression or until unacceptable toxicity.
- Refer to the Keytruda and Lenvima drug labels for dosing for all their other indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.